

Figure 8 Effect of PSI on the cell death and the levels of acrolein-modified protein. (A) Apoptotic and necrotic cell death after treatment with 10 and 100 nM PSI was quantified by staining the cells with 10 nM Hoechst 33342. The column and the bar represent the mean and SD of the number of dead cells, expressed as the percentage of the total. The open and the filled columns represent necrotic and apoptotic dead cells, respectively. The difference from the control cells is significant ($p < 0.05$) by ANOVA. (B) The effects of PSI on the level of acrolein-modified proteins were examined by immunoblot with antiacrolein antibody. The cytoplasmic (Cyt) P1 and P2 fractions of the cells treated with 10 and 100 nM of PSI for 24 hr were prepared by centrifugation at 800 *g* and 13,000 *g*, respectively.

may play a key role in the accumulation of oxidation-modified protein and neuronal death.

IV. MITOCHONDRIAL DYSFUNCTION INHIBITS THE PROTEASOME SYSTEM BY OXIDATIVE MODIFICATION

Systemic reduction in complex I of the mitochondrial electron transfer chains was reported in the nigro-striatum of patients

with PD (30,31,51). Recently, an inhibitor of complex I, rotenone, was reported to induce parkinsonism in rodents, and fibrillar cytoplasmic inclusions containing ubiquitin and α -synuclein were detected after the continuous administration (52). The effects of mitochondrial dysfunction on the proteasome system were studied by the use of rotenone at a concentration to induce apoptosis in the SH-SY5Y cells (50). ATP levels reduced markedly, and apoptosis was induced in the cells after 4–5 days treatment with rotenone. The oxidative modification of proteins was followed by the use of antibody against the acrolein-modified protein (19). The levels of the acrolein-modified protein increased markedly by rotenone treatment (Fig. 9).

The ubiquitin–proteasome system is a major site to remove damaged or mutated proteins and also regulatory proteins controlling cell cycle and signal transduction. In the nigro-striatum of the parkinsonian brain, the decreased activity of the proteasome was reported, suggesting its involvement in the pathological features (53). The oxidized protein is preferentially degraded *in vitro* by 20S proteasome in an ATP-independent way. 20S proteasome is composed of four rings to make a cylindrical structure, and each ring is made of seven α and β 20S subunits (54). Noncatalytic α -heptameric rings form each of the two outer rings and catalytic β -heptamers form the two inner rings. Binding of a regulatory subunit named 19S complex (ATPase, PA700) to both ends of the 20S cylinder produces 26S proteasome with a higher catalytic activity than the 20S proteasome. The 26S proteasome can degrade polyubiquitinated proteins and ornithine decarboxylase in an ATP-dependent process.

In the SH-SY5Y cells, rotenone treatment increased ROS–RNS levels only transitionally and slightly, whereas the oxidized protein levels increased progressively, suggesting that degradation of modified proteins may be mainly involved in the deposition. The enzymatic activity of proteasome measured with an artificial fluorescent substrate, carbobenzoxy-L-leucyl-L-leucyl-L-glutamic acid α -(4-methyl-coumaryl-7-amide) (*Z*-Leu-Leu-Glu-MCA), reduced in a time- and dose-dependent way, and virtually was not detected after 4 days treatment with




Figure 9 Effect of rotenone on oxidized protein level in SH-SY5Y cells. The cells were treated without or with 25 nM of rotenone for 5 days. The cells were fractionated into the cytoplasmic (Cyt), P1 and P2 fractions, and each fraction was subjected to immunoblotting, using antibody against acrolein-modified proteins. The aggregated proteins were observed in the stacking gel of the P1 fraction (arrow).

rotenone, as shown in Table 2. The reduction in the enzymatic activity was neither due to ATP depletion nor to the reduction of the protein level, indicating that the homospecific activity of proteasome decreased by the treatment. Indeed, the 20S β subunit protein was modified by acrolein, as shown by immunoprecipitation with anti-20S β subunit and by western blot analysis with the antiacrolein antibody. In this immunoprecipitant coprecipitated with 20S β subunit, oxidized proteins immunoreactive to antiacrolein antibody were detected in the cells treated with rotenone, suggesting that the acrolein-conjugated protein

Table 2 Effects of Rotenone Treatment on the Enzymatic Activity of Proteasome in SH-SY5Y Cells

Rotenone (25 nM)	ATP (2 mM)	Proteasome activity in SH-SY5Y cells treated with rotenone (pmol/min/ μ g protein)	
		After 6 hr	After 96 hr
Control	-	0.89 \pm 0.11*	5.19 \pm 0.47
	+	1.76 \pm 0.02	8.21 \pm 0.11
Sample	-	0.97 \pm 0.02	0.96 \pm 0.04
	+	2.25 \pm 0.02	1.80 \pm 0.13

Proteasome activity in the cytoplasmic fraction of the cells treated with 25 nM rotenone was measured fluorometrically in the absence or presence of exogenously added ATP (2 mM).

*Mean \pm SD of four experiments.

may be a substrate of 20S proteasome. However, further studies are required to clarify whether the acrolein-modified protein can directly inhibit proteasome activity, as in the case of the 4-HNE proteins (55). The increase in acrolein adducts after rotenone treatment may be comparable with that observed in the presence of PSI, as described earlier.

V. CONCLUSION

The results of this study suggest that mitochondrial dysfunction may induce degeneration of dopamine neurons through modification and inactivation of the proteasome system and subsequent aggregation of the oxidized proteins. The precise mechanism behind the cell death induced by oxidative stress requires further investigation, but it may be quite relevant to consider that the inactivation of proteasome may play a critical role in the activation of apoptotic signal. In neurodegenerative disorders, the environmental and genetic factors may induce a malignant cycle between mitochondrial dysfunction, increased oxidative stress, and reduced activity of proteasome in neurons, leading to the typical pathological

characteristics, cell death and formation of inclusion body. Our recent studies on the ubiquitin-proteasome system in the substantia nigra of human brains present further support to our hypothesis. In the parkinsonian brain, the 20S β subunit precipitated with the specified antibody was modified with acrolein, whereas that from control was not modified. Future studies may give a new insight into the mechanism of neuronal cell death in age and age-related disorders, and may give us clues for a new therapeutic strategy to protect neurons from apoptosis.

ACKNOWLEDGMENT

This work was supported by a Grant-in-Aid for Scientific Research on Priority Areas (C) from the Japan Society for the Promotion of Science (W.M.), a Grant for Clinical Research for Evidence Based Medicine for W.M. and M.N. from the Ministry of Health, Labor and Welfare, Japan.

REFERENCES

1. Halliwell B. Reactive oxygen species and the central nervous system. *J Neurochem* 1992; 59:1609-1623.
2. Stadtman ER. Protein oxidation and aging. *Science* 1992; 257: 1220-1224.
3. Kroemer G, Dallaporta B, Resch-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. *Annu Rev Physiol* 1998; 60:619-642.
4. Thompson CG. Apoptosis in the pathogenesis and treatment of disease. *Science* 1995; 267:1456-1462.
5. Cotman CW, Su JH. Mechanisms of neuronal death in Alzheimer's disease. *Brain Pathol* 1996; 6:493-506.
6. Kaytor MD, Warren ST. Aberrant deposition and neurological disease. *J Biol Chem* 1999; 274:37507-37510.
7. Beckman JS. Oxidative damage and tyrosine nitration from peroxynitrite. *Chem Res Toxicol* 1996; 9:836-844.

8. Pryor WA, Squandrito GL. The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. *Am J Physiol* 1995; 268:L699–L722.
9. Koppenol WH, Moreno JJ, Pryor WA, Ischiropoulos H, Beckman JS. Peroxynitrite, a cloaked oxidant formed by nitric oxide and superoxide. *Chem Res Toxicol* 1992; 5:834–842.
10. Kröncke KD, Fehsel K, Kolb-Bachofen V. Nitric oxide: cytotoxicity versus cytoprotection—how, why, when, and where? *Nitric Oxide* 1997; 1:107–120.
11. Halliwell B. What nitrates tyrosine? Is nitrotyrosine specific as a biomarker of peroxynitrite formation in vivo? *FEBS Lett* 1997; 411:157–160.
12. White R, Brock T, Cjang L, Crapo J, Briscoe P, Ku D, Bradley W, Gianturco S, Gore J, Freeman BA, Tarpey MM. Superoxide and peroxynitrite in atherosclerosis. *Proc Natl Acad Sci USA* 1994; 91:1044–1048.
13. Koppal T, Draake J, Yatin S, Jordan B, Varadarajan S, Bettenhausen L, Butterfield A. Peroxynitrite-induced alternation in synaptosomal membrane proteins: insight into oxidative stress in Alzheimer's disease. *J Neurochem* 1999; 72:310–317.
14. Smith M, Richey A, Harris PL, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. *J Neurosci* 1997; 17:2653–2657.
15. Good PF, Hsu A, Werner P, Perl DP, Olanow CW. Protein nitration in Parkinson's disease. *J Neuropathol Exp Neurol* 1998; 57:338–342.
16. Kato K, Ogino Y, Aoki T, Uchida K, Kawakishi S, Osawa T. Phenolic anti-oxidants prevent peroxynitrite-derived collagen modification in vitro. *J Agric Food Chem* 1997; 45:3004–3009.
17. Heinecke JW, Li W, Daehnke HL, Goldstein JA. Dityrosine, a specific marker of oxidant, is synthesized by the myeloperoxidase–hydrogen peroxide system of human neutrophils and macrophages. *J Biol Chem* 1993; 268:4069–4077.
18. Leeuwenburgh C, Rasmussen JE, Hsu FF, Mueller DM, Pannathur S, Heinecke JW. Mass spectrometric quantitation of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from

- human atherosclerotic plaques. *J Biol Chem* 1997; 272: 3520-3526.
19. Kato Y, Maruyama W, Naoi M, Hashizume Y, Osawa T. Immunohistochemical detection of dityrosine in lipofuscin pigments in the aged human brain. *FEBS Lett* 1998; 439:231-234.
 20. Esterbauer H, Schauer RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. *Free Radic Biol Med* 1991; 11:81-128.
 21. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. *Proc Natl Acad Sci USA* 1996; 93:2696-2701.
 22. Sayre LM, Zelasko DA, Harris PLR, Perry G, Salomon RG, Smith MA. 4-Hydroxynonenal-derived advanced lipid peroxidation and products are increased in Alzheimer's disease. *J Neurochem* 1997; 68:2092-2097.
 23. Yan SD, Chen X, Schmidt AM, Brett J, Godman G, Zou YS, Scott CW, Caputo C, Frappier T, Smith MA, Perry G, Yen SH, Stern G. Glycated tau protein in Alzheimer's disease: a mechanism for induction of oxidative stress. *Proc Natl Acad Sci USA* 1994; 91:7787-7791.
 24. Pedersen WA, Fu W, Keller JN, Markesbery WR, Appel S, Smith PG, Kasarkis E, Mattson MP. Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. *Ann Neurol* 1998; 44:819-824.
 25. Gan JC, Cardasan A, Ansari GA. In vitro modification of serum albumin by acrolein. *Chemosphere* 1999; 23:939-947.
 26. Uchida K, Kanematsu M, Motimistu Y, Osawa T, Noguchi N, Niki F. Acrolein a product of lipid peroxidation: formation of free acrolein and its conjugate with lysine residues in oxidized low density lipoproteins. *J Biol Chem* 1998; 273:16058-16066.
 27. Calingoson NY, Uchida K, Gibson GE. Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer's disease. *J Neurochem* 1999; 72:751-756.
 28. Crow JP. Dichlorodihydrofluorescein and dihydrorhodamine 123 are sensitive indicators of peroxynitrite in vitro: implications for

- intracellular measurement of reactive nitrogen and oxygen species. *Nitric Oxide* 1997; 1:145–157.
29. Tanaka M, Miyabayashi S, Nishikimi M, Suzuki H, Shimomura Y, Ito K, Narisawa K, Tada K, Ozawa K. Extensive defects of mitochondrial electron-transfer chain in muscular cytochrome *c* oxidase deficiency. *Pediatr Res* 1988; 24:447–454.
 30. Schapira AHV, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. *Lancet* 1989; 1:1269.
 31. Mizuno Y, Ohta S, Tanaka M, Takemiya S, Suzuki K, Sato T, Oya H, Ozawa T, Kagawa Y. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. *Biochem Biophys Res Commun* 1989; 163:1450–1455.
 32. Maruyama W, Takahashi T, Naoi M. (-)Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite nitric oxide. *J Neurochem* 1998; 70:2510–2515.
 33. Oh-hashii K, Maruyama W, Yi H, Takahashi T, Naoi M, Isobe M. Mitogen-activated protein kinase pathway mediates peroxynitrite-induced apoptosis in human dopaminergic neuroblastoma SH-SY5Y cells. *Biochem Biophys Res Commun* 1999; 263:504–509.
 34. Maruyama W, Kato Y, Yamamoto T, Oh-hashii K, Hashizume Y, Naoi M. Peroxynitrite induced neuronal cell death in aging and age-associated disorders. *J Am Aging Assoc* 2001; 24:11–18.
 35. Yamamoto T, Maruyama W, Kato Y, Yi H, Shamoto-Nagai M, Tanaka M, Sato Y, Naoi M. Selective nitration of mitochondrial complex I by peroxynitrite: involvement in mitochondrial dysfunction and cell death of dopaminergic SH-SY5Y cells. *J Neural Transm* 2002; 109:1–13.
 36. Hortelano S, Alvarez AM, Bosca L. Nitric oxide induces tyrosine nitration and release of cytochrome *c* preceding an increase of mitochondrial transmembrane potential in macrophages. *FASEB J* 1999; 13:2311–2317.
 37. Cassina AM, Hondara R, Souza JM, Thomson I, Castro L, Ischiropoulos H, Freeman BA, Radi R. Cytochrome *c* nitration by peroxynitrite. *J Biol Chem* 2000; 275:21409–21415.

38. Radi R, Rodriguez M, Castro L, Telleri R. Inhibition of mitochondrial electron transport by peroxynitrite. *Arch Biochem Biophys* 1994; 308:89–95.
39. Brorson JB, Schumacker PT, Zhang H. Nitric oxide acutely inhibits neuronal energy production. *J Neurosci* 1999; 19:147–158.
40. Bolanos JP, Almeida A, Stewart V, Peuchen S, Land JM, Clark JB, Heales SJR. Nitric oxide-mediated mitochondrial damage in the brain: mechanisms and implications for neurodegenerative disease. *J Neurochem* 1997; 68:2227–2240.
41. Beltran B, Quinetto M, Garcia-Zaragoza E, O'Connor E, Esplugues JV, Moncada S. Inhibition of mitochondrial respiration by endogenous nitric oxide: a critical step in Fas signaling. *Proc Natl Acad Sci USA* 2002; 99:8892–8897.
42. Iwatsubo T, Yamaguchi H, Fujikura M, Yokosawa H, Ihara Y, Trojanowski JQ, Lee VM. Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. *Am J Pathol* 1996; 148:1517–1529.
43. Ii K, Ito H, Tanaka K, Hirano A. Immunocytochemical colocalization of the proteasome in ubiquitinated structures in neurodegenerative disease and the elderly. *J Neuropathol Exp Neurol* 1997; 56:125–131.
44. Spillantini MG, Schmidt ML, Lee VM-Y, Trojanowski JQ, Jakes R, Goedert M. α -Synuclein in Lewy bodies. *Nature* 1997; 388:837–840.
45. Choi P, Osrerova-Golts N, Sparkman D, Cochran E, Lee JM, Wolozin B. Parkin is metabolized by the ubiquitin/proteasome system. *Neuroreport* 2000; 11:2635–2638.
46. Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, Mizuno Y, Kosik KS, Selkoe DJ. Ubiquitination of a new form of alpha-synuclein by Parkin from human brain: implication for Parkinson's disease. *Science* 2001; 293:263–269.
47. Tanaka Y, Engelender S, Igarashi S, Rao PK, Wanner T, Tanzi RE, Sawa A, Dawson VL, Dawson TM, Ross CA. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. *Hum Mol Genet* 2001; 10:919–926.

48. Trojanowski JQ, Goedert M, Iwatsubo T, Lee VM-Y. Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. *Cell Death Differ* 1998; 8:832-837.
49. Souza JM, Giasson BI, Chen Q, Lee M-Y. Dityrosine cross-linkage promotes formation of stable α -synuclein polymers. *J Biol Chem* 2000; 275:18344-18349.
50. Shamoto-Nagai M, Maruyama W, Kato Y, Isobe K, Tanaka M, Naoi M, Osawa T. An inhibitor of mitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH-SY5Y cells. *J Neurosci Res* 2003; 74:589-597.
51. Hattori N, Tanaka M, Ozawa T, Mizuno Y. Immunohistochemical studies on complex I, II, III, and IV of mitochondria in Parkinson's disease. *Ann Neurol* 1991; 30:563-571.
52. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. *Nat Neurosci* 2000; 3:1301-1306.
53. McNaught KSP, Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. *Neurosci Lett* 2001; 297:191-194.
54. Hough R, Pratt G, Rechsteiner M. Purification of two high molecular weight proteasomes from rabbit reticulocyte lysate. *J Biol Chem* 1987; 262:8303-8313.
55. Okada K, Wangpoengtrakui C, Osawa T, Toyokuni S, Tanak K, Ucida K. 4-Hydroxy-2-nonenal-mediated impairment of intracellular proteolysis during oxidative stress. *J Biol Chem* 1999; 274:23787-23793.

Oxidative Stress in Mitochondria

Decision to Survival and Death of Neurons in Neurodegenerative Disorders

**Makoto Naoi,^{*,1} Wakako Maruyama,² Masayo Shamoto-Nagai,²
Hong Yi,¹ Yukihiro Akao,¹ and Masashi Tanaka¹**

¹*Gifu International Institute of Biotechnology, Kakamigahara, Gifu, Japan; and* ²*Department of Geriatrics, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan*

Abstract

In mitochondria, oxidative phosphorylation and enzymatic oxidation of biogenic amines by monoamine oxidase produce reactive oxygen and nitrogen species, which are proposed to cause neuronal cell death in neurodegenerative disorders, including Parkinson's and Alzheimer's disease. In these disorders, mitochondrial dysfunction, increased oxidative stress, and accumulation of oxidation-modified proteins are involved in cell death in definite neurons. The interactions among these factors were studied by use of a peroxynitrite-generating agent, *N*-morpholino sydnonimine (SIN-1) and an inhibitor of complex I, rotenone, in human dopaminergic SH-SY5Y cells. In control cells, peroxynitrite nitrated proteins, especially the subunits of mitochondrial complex I, as 3-nitrotyrosine, suggesting that neurons are exposed to constant oxidative stress even under physiological conditions. SIN-1 and an inhibitor of proteasome, carbobenzoxy-L-isoleucyl- γ -*t*-butyl-L-alanyl-L-leucinal (PSI), increased markedly the levels of nitrated proteins with concomitant induction of apoptosis in the cells. Rotenone induced mitochondrial dysfunction and accumulation and aggregation of proteins modified with acrolein, an aldehyde product of lipid peroxidation in the cells. At the same time, the activity of the 20S β -subunit of proteasome was reduced significantly, which degrades oxidative-modified protein. The mechanism was proved to be the result of the modification of the 20S β -subunit with acrolein and to the binding of other acrolein-modified proteins to the 20S β -subunit.

Increased oxidative stress caused by SIN-1 treatment induced a decline in the mitochondrial membrane potential, $\Delta\Psi_m$, and activated mitochondrial apoptotic signaling and induced cell death in SH-SY5Y cells. As another pathway, p38 mitogen-activated protein (MAP) kinase and extracellular signal-regulated kinase (ERK) mediated apoptosis induced by SIN-1. On the other hand, a series of neuroprotective propargylamine derivatives, including rasagiline [*N*-propargyl-1(*R*)aminoindan] and (-)-deprenyl, intervened in the activation of apoptotic cascade by reactive oxygen species-reactive nitrogen species in mitochondria through stabilization of the membrane

Received 6/21/04; Accepted 11/15/04.

* Author to whom all correspondence and reprint requests should be addressed. E-mail: mnaoi@giib.or.jp

potential, $\Delta\Psi_m$. In addition, rasagiline induced antiapoptotic Bcl-2 and glial cell line-derived neurotrophic factor (GDNF) in SH-SY5Y cells, which was mediated by the ERK–nuclear factor (NF)- κ B pathway. These results are discussed in relation to the interaction of oxidative stress and mitochondria in the regulation of neuronal death and survival in neurodegenerative diseases.

Index Entries: Oxidative stress; mitochondria complex I; proteasome; 3-nitrotyrosine; acrolein; Parkinson's disease; apoptosis; rasagiline; transcription factors.

Oxidative-Modified Protein as the Marker of Oxidative Stress

Oxidative stress has been proposed as one of the major causes inducing neuronal death in aging and age-associated disorders (1), and mitochondria produce most of reactive oxygen and nitrogen species (ROS and RNS, respectively) in the cells. The superoxide anion radical is generated by oxidative phosphorylation in mitochondria and reacts with nitric oxide (NO) to produce peroxynitrite (ONOO⁻), one of the most potent radicals. On the other hand, oxidation of biogenic amines by monoamine oxidase in the mitochondrial outer membrane generates hydrogen peroxide. Mitochondria are now considered to play a pivotal role in apoptosis (2), which is the common death type of neurons in Parkinson's (PD) and Alzheimer's diseases (AD) (3). The role of mitochondria in the process of apoptotic commitment is recognized, and impairment of energy charge and redox, permeability transition (PT), disruption of membrane potential ($\Delta\Psi_m$), and release of cytochrome-*c* are observed prior to fragmentation of nuclear DNA, a hallmark of apoptotic morphological features.

Neurodegenerative disorders are characterized by a decline of specified neurons in selected brain regions, associated with protein deposits specific for each disease. In PD, dopamine neurons in the substantia nigra degenerate progressively with formation of Lewy bodies (LBs). The pathogenesis of PD remains as an enigma, but PD is considered a consequence of various genetic and environmental interactions. The vulnerability of the neurons might be the result of increased generation of ROS and RNS, reduced antioxidant

capacity, high contents of iron and dopamine, and mitochondrial dysfunction in nigral dopamine neurons. ROS and RNS generated in mitochondria modify bioactive molecules, such as lipids, proteins, DNA, and carbohydrates, either directly or indirectly with peroxidation products of lipid or carbohydrates. 4-Hydroxynonenal (4-HNE) and acrolein, aldehyde products of lipid peroxidation, are cytotoxic, and aldehyde-modified proteins were increased in dopamine neurons of the nigro-striatum in PD (4), neurofibrillary tangles in AD (5), and the spinal cord in amyotrophic lateral sclerosis (ALS) (6). Figure 1 shows the accumulation of 4-HNE-modified protein in the substantia nigra of parkinsonian brain. Dopamine neurons containing neuromelanin were selectively modified with 4-HNE more markedly in the PD brain than those in the control or in cells other than dopamine neurons. This suggests the essential role of dopamine in increased oxidative stress.

One of the most active RNS, ONOO⁻, nitrates sulfhydryl and hydroxyl residues in cysteine, methionine, phenylalanine, and tyrosine, and the modification inactivates the membrane function and key enzymes (7). 3-Nitrotyrosine (3-NT) is synthesized by nitration of tyrosine residues in protein and a marker for the oxidative stress induced by ONOO⁻ in vivo (8). An increase in 3-NT-containing protein (3-NT protein) was observed in atherosclerosis (9), ALS (6), AD (10), and PD (11). Another oxidation product of tyrosine is dityrosine, which is produced from free and protein-bound tyrosine in the presence of hydrogen peroxide and myeloperoxidase and was detected in atherosclerotic plaques and lipofuscin pigments in the aged human brain (12).




Fig. 1. 4-HNE-modified protein in the substantia nigra of the parkinsonian brain. In dopamine neurons containing neuromelanin, proteins stained with the anti-4-HNE antibody increased in the parkinsonian brain, but were not detected in the age-matched control.

Oxidative modification produces aggregated and crosslinked proteins, which are resistant to proteolytic degeneration and difficult to removed from cells. Accumulation of modified proteins might impact on a variety of cellular functions by changing the enzymatic, regulatory, and transporting potencies of specific proteins, in addition to occupying space in the limited cellular volume. The level of oxidized proteins might reflect the balance between the generation of ROS-RNS and degradation of modified protein, in which the ubiquitin-proteasome system plays a key role (13), as discussed in the following sections.

Mitochondrial Complex I Subunits Are Major Targets of ONOO⁻

In the brain, NO has been thought to be produced in microglia and astrocytes and transported to neurons, where it reacts with superoxide, yielding ONOO⁻. However, NO is synthesized also *in situ* in the neurons and functions as a neuromodulator (14). Using an

antibody against 3-NT protein (15), nitrated proteins were detected in control brains. In brains from AD and PD patients, the same proteins stained with anti-3NT antibody as in control increased markedly, indicating that ONOO⁻ preferentially modified selective proteins in neuronal cells under physiological and pathological conditions. Figure 2 shows the presence of 3-NT protein in control SH-SY5Y cells almost at the same levels as in the cells treated with ONOO⁻-generating *N*-morpholino sydnomine (SIN-1), indicating that the cells are exposed to constant oxidative stress. However, the control cells are intact in growth and proliferation, and under physiological conditions, an active mechanism functions to eliminate modified protein from the cells and to protect cellular function in neuronal cells.

As shown in Fig. 3, the presence of nitrated protein in control cells was confirmed further by the Western blot analysis of the subcellular fractions of SH-SY5Y cells. In mitochondrial fraction, 3-NT protein was detected in the subunits of complex I stained with that against mitochondria complexes I, II, III, and IV,




Fig. 2. 3-NT protein detected in control SH-SY5Y cells and cells treated with ONOO⁻-generating SIN-1. In cytoplasm, 3-NT proteins were detected by staining with anti-3-NT antibody (15). Note that the 3-NT protein was detected also in the control.

respectively (16), (Fig. 3). These results suggest that complex I subunits are nitrated preferentially and the modification might contribute to mitochondrial dysfunction observed in the nigro-striatum of the parkinsonian brain (17).

ONOO⁻-generating SIN-1 induced apoptosis in SH-SY5Y cells (14,18–20) and inhibited ATP synthesis in mitochondria. The inhibition might be the result of the binding of NO and ONOO⁻ to cytochrome oxidase or inactivation of complexes II and III and ATPase (21). However, SIN-1 treatment did not increase 3-NT protein as markedly. These seemingly contradicting results indicate again that the levels of oxidative stress and oxidative-modified protein are regulated by the degradation rate rather than the production of ROS-RNS.

Proteasome Plays a Key Role in Accumulation of Oxidized Proteins

Insoluble protein aggregates, such as LBs in PD and senile plaques composed of β -amyloid in AD, are hallmarks of neurodegeneration. However, it remains to be clarified whether

Stained with antibody against

3-NT Mitochondrial complex




Fig. 3. 3-NT proteins in the subunits of mitochondrial complex I. Mitochondria were prepared from SH-SY5Y cells and subjected to Western blot analysis using antibody against 3-NT protein or mitochondrial complex I, II, III, and IV, respectively.

protein aggregates cause neuronal cell death directly or are the results of deteriorated cellular homeostasis in dying neurons. Protein aggregation is considered a manifestation of




Fig. 4. Effects of ONOO⁻-generating SIN-1 and a proteasome inhibitor, PSI, on 3-NT levels in SH-SY5Y cells. After incubated for 0.5, 1, 3, and 6 h, the cells were subjected to the immunoblotting analysis with anti-3-NT antibody. PSI increased 3-NT in the same proteins as in control and SIN-1-alone-treated cells.

disturbed cellular protein-folding homeostasis maintained by the ubiquitin-proteasome system. Ubiquitinated proteins and proteasome subunits (22,23), in addition to α -synuclein, Parkin and ubiquitin C-terminal hydrolase-L1 (UCH-1) (24–27), are the components of LBs and are sometimes modified with ROS-RNS.

To clarify the interactions among oxidative stress, dysfunction of the proteasome system, and formation of the inclusion body, the effects of a proteasome inhibitor, carbobenzoxy-L-isoleucyl- γ -*t*-butyl-L-alanyl-L-leucinal (PSI) were examined on the aggregation of oxidative-modified proteins and the cell vulnerability (20,28). PSI increased the amount of 3-NT proteins in SH-SY5Y cells, but the number of 3-NT proteins was almost the same as in the control (Fig. 4). At the same time, the number of apoptotic cells increased significantly by PSI, but that of necrotic cells was not (Fig. 5). These results indicate that inhibition of proteasome activity might play a key role in the accumulation of oxidative-modified protein and the induction of cell death.

Rotenone, a Complex I Inhibitor, Inactivates Proteasome by Oxidative Modification

The activity and protein of complex I of the mitochondrial electron transfer chains reduced in the nigro-striatum of patients with PD (17). The systemic administration of rotenone, an inhibitor of complex I, induced parkinsonism in rodents, and fibrillar cytoplasmic inclusions containing ubiquitin and α -synuclein were detected in dopamine neurons (29). The effects of mitochondrial dysfunction on the proteasome system were studied by use of rotenone (28). Apoptosis was induced in the cells after 4–5 d treatment with rotenone. The oxidative modification of proteins was followed by the use of an antibody against acrolein-modified protein (30). As shown in Fig. 6, the levels of acrolein-modified protein increased markedly by the rotenone treatment. In the lysate of rotenone-treated cells, aggregation of acrolein-modified protein with high molecular mass was also detected.

The ubiquitin-proteasome system is a major site for removal of damaged or modified proteins and also regulatory proteins controlling cell cycle and signal transduction. In the nigro-striatum of the parkinsonian brain, the decreased activity of proteasome was reported, suggesting its involvement in the pathological features (31). Oxidized protein is preferentially degraded *in vitro* by 20S proteasome in an ATP-independent way. Binding of the regulatory subunit, 19S complex (ATPase, PA700), to both ends of the 20S cylinder produces 26S proteasome with higher catalytic activity than 20S proteasome. 26S proteasome degrades polyubiquitinated proteins and ornithine decarboxylase in an ATP-dependent process.

In SH-SY5Y cells, the rotenone treatment increased ROS-RNS levels detected with 2,7-dichlorofluorescence diacetate only transitionally and slightly, whereas the oxidized protein levels increased progressively, suggesting that protein might function as “the second scavenger” of ROS-RNS and that degradation of modified proteins might be impaired. The




Fig. 5. Cytotoxic effect of PSI treatment on SH-SY5Y cells. The cells were treated with or without PSI for 24 h. (A) Phase-contrast microscopy; (B) nuclear staining with Hoechst 33342, (C) quantitative measurement of apoptotic and necrotic cells. Apoptotic cells were assessed from condensed nuclei stained with Hoechst 33342. The column and the bar represent the mean and SD of the number of dead cells, respectively, expressed as the percentage of the total. The open and the filled columns represent necrotic and apoptotic dead cells, respectively. * $p < 0.05$ from control.




Fig. 6. Acrolein-modified protein in rotenone-treated SH-SY5Y cells. The cells were treated with 5 μ M rotenone (+) or without (-) for 3 d and the sub-cellular fractions were prepared. I: cytoplasm; II: P₁ fraction (nuclei, plasma membrane); III: P₂ fraction (mitochondria). Proteins were immunoblotted with an antibody against acrolein-modified protein. In the P₁ fraction, aggregated acrolein-modified proteins were detected at the top of the gel.

enzymatic activity of proteasome (post-glutamyl peptidase-like activity) measured with a synthetic fluorescent substrate, carbobenzoxy-L-leucyl-L-leucyl-L-glutamic acid α -(4-methylcoumaryl-7-amide) [Z-Leu-Leu-Glu-MCA],

reduced in a time- and dose-dependent way and virtually was not detected after 4 d treatment with rotenone, as shown in Table 1.

The lysate of rotenone-treated cells was immunoprecipitated with antibody against the

Table 1
Effects of Rotenone Treatment on Proteasome Activities in SH-SY5Y Cells

Rotenone (25 nM)	ATP (2 mM)	Proteasome activity in SH-SY5Y cells treated with rotenone (pmole/min/ μ g protein)	
		After 6 h	After 96 h
Control	-	0.89 \pm 0.11 ^a	5.19 \pm 0.47
	+	1.76 \pm 0.02	8.21 \pm 0.11
Sample	-	0.97 \pm 0.02	0.96 \pm 0.04
	+	2.25 \pm 0.02	1.80 \pm 0.13

Cytoplasmic fraction was prepared from the cells treated with 25 nM rotenone. Postglutamyl peptidase-like proteasome activity was measured fluorometrically using Z-Leu-Leu-Glu-MCA as a substrate with or without the addition of ATP (2 mM).

^a Mean \pm SD of four experiments.




Fig. 7. Modification of the 20S β -subunit of proteasome with acrolein after treatment with rotenone. The cells were treated with 25 μ M rotenone (rotene-treated) or without (control) for 4 d, lysed, and precipitated with antibody against the 20S β -subunit. The immunoprecipitant was subjected to Western blot analysis with antibody against acrolein-modified protein. The 20S β -subunit in the precipitant was visualized with anti-20S β -antibody (20S β). A filled arrow shows that 20S β was modified with acrolein.

20S β -subunit and the subunit protein was modified by acrolein, as shown by Western blot analysis with anti-acrolein antibody (Fig. 7). Acrolein-modified proteins other than the 20S β -subunit were also detected in the immunoprecipitant, suggesting that the oxidized proteins might serve as substrates of 20S proteasome and the aggregated ones might inhibit the activity. However, it requires further

studies to clarify whether the acrolein-modified protein can directly inhibit the proteasome activity, as in the case of 4-HNE proteins (32).

Apoptotic Signal Activated by ROS-RNS

Both SIN-1 and NO induce apoptosis in SH-SY5Y cells by opening a megachannel called mitochondrial permeability transition pore (mPTP) with a decline in mitochondrial membrane potential ($\Delta\Psi_m$), as shown in Fig. 8. Opening of mPTP induces matrix swelling and physical disruption of the outer membrane in mitochondria and the release of Ca^{2+} , cytochrome-*c*, and apoptosis-inducing factors into cytoplasm. The mPTP is a protein complex composed of a voltage-dependent anion channel and other components located at the contact site between the mitochondrial outer membrane and inner membrane, and the opening is regulated by Bcl-2 in the outer membrane and the adenine nucleotide translocator in the inner membrane (2). Bcl-2 family proteins regulate cell death induced by oxidative stress and other stimuli, either in a preventing way (Bcl-2 and Bcl-xL) or a promoting way (Bax, Bad, and Bid). The antiapoptotic function of Bcl-2 is mediated by maintaining




Fig. 8. Reduction in $\Delta\Psi_m$ by SIN-1 treatment and the effect of neuroprotective rasagiline. SH-SY5Y cells were treated with SIN-1 (250 μM) for 1 h, with or without pretreatment with 0.1 μM rasagiline, and stained with 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethyl-benzimidazolcarbocyanine iodide (JC-1). The level of $\Delta\Psi_m$ was determined from red fluorescence, indicating JC-1 aggregates in intact mitochondria.

mitochondria–cytosolic coupling of oxidative phosphorylation, preventing the opening of mPTP and functioning as an antioxidant, either directly or by upregulating other ROS scavengers.

The opening of the mPTP by ONOO^- has been considered to be the result of the nitration of tyrosine residues in the mPTP to release cytochrome-*c* (33) or of cytochrome-*c* itself (34), of the oxidative crosslinking of thiol groups with protein amalgamation and pore formation, or of the lipid peroxidation to generate 4-HE and acrolein with the potential to induce permeability transition. As another mechanism, ONOO^- might modify the Bcl-2 family and change the localization and function, as in the case of Bax (35). The opening of the mPTP activates caspase-3, the executor of apoptosis, as shown in Fig. 9 A, induces translocation of glyceraldehydes-3-phosphate dehydrogenase (GPDH) into nuclei, and, finally, fragmentation of nuclear DNA.

Aside from apoptotic signaling in mitochondria, several different protein kinases, including p38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK), were reported to be involved in apoptosis induced by ROS-RNS (36–38). As shown in Fig. 9 B, an inhibitor of p38 MAPK, SB202190, prevented the activation of caspase-3 and apoptosis

induced by ONOO^- , suggesting that p38 MAPK might be also involved in apoptosis induced by ONOO^- . In addition, ONOO^- activated extracellular signal-regulated kinase (ERK) kinase (MEK1), the phosphorylation of which was inhibited by PD98059, a selective inhibitor, and also by superoxide dismutase (SOD) plus catalase, which catalyzes superoxide into H_2O via H_2O_2 (14,19). Interestingly, SB202190 attenuated the activation of ERK kinase, but it remains to be clarified whether p38 MAPK and MEK1 interact with each other and whether the activation of kinases is the consequence of mitochondrial death signaling or vice versa.

Mitochondria and Cell Signaling Mediate Neuroprotective Function of Propargylamines

Neuroprotection is a new therapeutic strategy to slow or halt the progression of PD and other neurodegenerative disorders (39–42). The apoptotic cascade, which is activated sequentially and progresses rather slowly, is proposed as a target of neuroprotection (3). Recently, a series of propargylamine derivatives, rasagiline (a secondary cyclic benzylamine), (–)deprenyl (a tertiary aralkylamine),




Fig. 9. Activation of caspase-3 by SIN-1 and suppression by a p38 inhibitor, SB202190. (A) The cells were treated with SIN-1, and caspase-3 activity in the cell lysate was measured with Asp-Glu-Val-As-4-methylcumaryl-7-amide as a substrate. (B) the cells were treated with 40 μ M SB202190 and then 10 μ M SIN-1 for 18 h; then, the activities of caspase-3 were determined. * $p < 0.01$ compared to the control.

and 2-HMP [*N*-(2-hexyl)-*N*-methyl-propargylamine, a tertiary branched alkylamine], have been proved to protect neurons from cell death induced by ROS-RNS, neurotoxins, and other stimuli (41–47). At present, rasagiline is the most potent in preventing apoptosis. The hitherto-confirmed mechanism underlying the neuroprotection by propargylamines is shown in Fig. 10. Rasagiline prevents the decline in $\Delta\Psi_m$ and swelling of mitochondria (Figs. 8 and 10), the release of cytochrome-*c*, nuclear GAPDH translocation, and fragmentation of nuclear DNA. The antiapoptotic function of rasagiline has been proved to be the result of (1) the stabilization of $\Delta\Psi_m$ and suppression of mPT (47,48) and (2) the induction of antiapoptotic, prosurvival genes of Bcl-2 (48–50), glial cell line-derived neurotrophic factor (GDNF) (51), and antioxidative enzymes, catalase and SOD (52). The activation of the nuclear factor- κ B (NF- κ B) pathway has been confirmed to mediate the induction of antiapoptotic genes (51). Rasagiline induced the phosphorylation of the inhibitory subunit (I κ B) of NF- κ B, and the active p65 subunit was translocated into

nuclei (Fig. 11A). In addition, an inhibitor of I κ B kinase, sulfasalazine, suppressed the activation of NF- κ B and also the induction of GDNF (51) and *bcl-2* by rasagiline (Fig. 11B). NF- κ B is one of the most important transcription factors and is activated by various pathogenic stimuli, including oxidative stress, ischemic insults, and β -amyloid. The induction of antiapoptotic genes depends on the stereochemical structure of rasagiline, suggesting that the binding site in mitochondria might mediate signaling for antiapoptotic gene expression. In addition, we found that ERK kinase was also activated by rasagiline, as an upper stream signal of NF- κ B activation. It is interesting that ERK is involved in either proapoptotic signaling through p38 kinase and also in the antiapoptotic pathway through NF- κ B. The regulation of these opposite signals should be elucidated to find new drugs suppressing apoptotic cascade and protecting neurons. The stress signaling from mitochondria to nuclei also remains to be elucidated, but the activation of the NF- κ B pathway might play a key role, as reported recently (53).





Fig. 10. Mechanisms behind neuroprotective function of propargylamines. Rasagiline prevents opening of the mitochondrial permeability transition (mPT) pore (PTP) and suppresses the mitochondrial swelling, as shown by the light scattering of isolated mitochondria. Rasagiline activates ERK and the NF-κB pathway and induces antiapoptotic Bcl-2, GDNF, and antioxidant enzymes. *bcl-2* mRNA was increased by rasagiline in a dose-dependent way.

A p65 NF-κB in nuclear fraction



B mRNA of *bcl-2* family




Fig. 11. Activation of NF-κB and induction of antiapoptotic *bcl-2* mRNA by rasagiline. (A) Translocation of activated NF-κB in nuclei. SH-SY5Y cells were treated with rasagiline, and in the nuclear fraction, active p65 NF-κB increased with 1 μM and 100 nM rasagiline in a time-dependent way. (B) Sulfasalazine, an inhibitor of IκB kinase suppressed rasagiline-induced induction of the antiapoptotic *bcl-2* family. After treatment with rasagiline, mRNA was subjected to reverse transcription–polymerase chain reaction analysis for the *bcl-2* family. Sulfasalazine suppressed the increase of *bcl-2*, *bcl-xL*, and *mcl-1* by rasagiline. Proapoptotic *bax* was not affected by rasagiline.